



References


1. **Aadland E., Schrumpf E., Fausa O., et al. (1987):** Primary sclerosing cholangitis: a long-term follow-up study. *Scand J Gastroenterol*; 22: 655-664.
2. **Abenavoli L., Corpechot C. and Poupon R. (2007):** Elastography in hepatology. *Can J Gastroenterol* 21(12):839–842.
3. **Abraham S.C. and Burgart L.J. (2004):** Isolated centrilobular hepatitis: a distinctive histologic lesion with several clinicopathologic associations. *Mod Pathol*; 17S1:294A.
4. **Agarwal K., Czaja A.J. and Donaldson P.T. (2007):** A functional fas promoter polymorphism is associated with a severe phenotype in type I autoimmune hepatitis characterised by early development of cirrhosis. *Tissue Antigens* 2007.
5. **Agarwal K., Czaja A.J., Jones D.E.J. et al. (2000):** CTLA-4 polymorphisms and susceptibility to type I autoimmune hepatitis. *Hepatology*; 31:49-53.
6. **Akira S., Uematsu S. and Takeuchi O. (2006):** Pathogen recognition and innate immunity. *Cell*; 124:783-801.
7. **Alvarez F., Berg P.A., Bianchi F.B. et al. (1999):** International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. *J Hepatol*; 31:929–938.
8. **Amano K., Takahashi H., Kuniyasu Y. et al. (2001):** The combination of CTLA-4 and IFN- γ gene polymorphism is associated with susceptibility to PBC and influence on clinical manifestation. *Hepatology*, 34:371A (Abstract 797),




9. **Angulo P., Peter J.B., Gershwin M.E. et al. (2000):** Serum autoantibodies in patients with primary sclerosing cholangitis. *J Hepatol*; 32: 182-187.
10. **Bach N., Thung S.N. and Schaffner F. (1992):** The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. *Hepatology*; 15:572–577.
11. **Balasubramaniam K., Wiesner R.H. and LaRusso N.F. (1988):** Primary sclerosing cholangitis with normal serum alkaline phosphatase activity. *Gastroenterology* 1988;95:1395-8.
12. **Bambha K., Kim W.R., Talwalkar J. et al. (2003):** Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. *Gastroenterology*; 125:1364-9.
13. **Bansal A.S., Thomson A., Steadman C. et al. (1997):** Serum levels of inter-leukins 8 and 10, interferon gamma, granulocyte-macrophage colony stimulating factor and soluble CD23 in patients with primary sclerosing cholangitis. *Autoimmunity*; 26:223-229.
14. **Bansi D., Chapman R. and Fleming K. (1996):** Antineutrophil cytoplasmic antibodies in chronic liver diseases: Prevalence, titre, specificity and IgG subclass. *J Hepatol*; 24:581-6.
15. **Bataller R., North K.E. and Brenner D.A. (2003):** Genetic polymorphisms and the progression of liver fibrosis' a critical appraisal *Hepatology*; 37:493-503.
16. **Bauer S., Groh V., Wu J. et al. (1999):** Activation of NK cells and T cells by NKG2D. a receptor for stress inducible MICA. *Science*; 285: 727-729.




-
17. **Bensen J.T., Langfeld C.D., Hawkins G.A. et al. (2003):** Nucleotide variation, haplotype structure, and association with end stage renal disease Of the human interleukin-1 gene cluster. *Genomics*; 82: 194-217.
18. **Bergasa N.V. (2005):** The pruritus of cholestasis. *J Hepatol* 43 (6): 1078–1088.
19. **Bernal W., Moloney M., Underhill J. et al. (1999):** Association of tumour necrosis factor polymorphism with primary sclerosing cholangitis *J Hepatol*. 30:237-241.
20. **Bittencourt L.P., Palacios S.A., Cancado E.L.R. et al. (2001):** Autoimmune hepatitis in Brazilian patients is not linked to tumour necrosis factor polymorphisms at position -308. *Hepato*; 35:24-28.
21. **Bittencourt P.L., Palacios S.A., Cancado E.L. et al. (2002):** Susceptibility to primary sclerosing cholangitis in Brasil is associated with HLA-DRB 1*13 but not with tumour necrosis factor alpha-308 promoter polymorphism. *Gut*; 51:609-610.
22. **Bjornsson E. and Angulo P. (2007):** Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. *Am J Gastroenterol*; 102:1677-82.
23. **Bjornsson E., Lindqvist-Ottosson J., Asztely M. et al.. (2004):** Dominant strictures in patients with primary sclerosing cholangitis. *Am J Gastroenterol*; 99:502-8.
24. **Blachar A., Federle M.P. and Brancatelli G. (2001):** Primary biliary cirrhosis: clinical, pathologic, and helical CT findings in 53 patients. *Radiology* 220(2):329–336.




- 25.**Bo X., Broome U., Remberger M. et al. (2001):** Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. *Gut*; 49:131-141.
- 26.**Boberg K.M. (2002):** Prevalence and epidemiology of autoimmune hepatitis. *Clin Liver Dis*; 6:347–359.
- 27.**Boberg K.M., Aadland E., Jahnsen J. et al. (1998):** Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. *Scand J Gastroenterol*; 33:99-103.
- 28.**Boberg K.M., Spurkland A., Rocca G. et al. (2001):** The HLA-DR3. DQ2 heterozygous genotype is associated with an accelerated progression in primary sclerosing cholangitis. *Scand J Gastroenterol*. 36:886-890.
- 29.**Briggs D.C., Donaldson P.T., Hayes P. et al. (1987):** A major histocompatibility complex Class III allotype C4B2 associated with primary biliary cirrhosis. *Tissue Antigen*; 29:141-145.
- 30.**Brigl M. and Brenner MB. (2004):** CD1: antigen presentation and T cell function. *Annu Rev Immunol*; 22:817-890.
- 31.**Brooke B.N., Dykes P.W., FC W. (1961):** A study of liver disorder in ulcerative colitis. *Postgrad Med Jol*; 37:245-251.
- 32.**Broome U., Hultcrantz R., Lefvert A.K., et al. (1998):** Cytokine production from colonic T cells in patients with ulcerative colitis with and without primary sclerosing cholangitis. *Dis Colon Rectum*; 41:1543-1549.




- 33.**Burak K.W., Angulo P. and Lindor K.D. (2003):** Is there a role for liver biopsy in primary sclerosing cholangitis? *Am J Gastroenterol*; 98:1155-8.
- 34.**Burroughs A.K. (1984):** Bacteriuria and primary biliary cirrhosis. *Gut* 25(2):133–137.
- 35.**Carlson C.S., Eberle M.A., Kruglyak L. et al. (2004):** Mapping complex disease loci in whole genome association studies. *Nature*; 429:446-452.
- 36.**Cauch-Dudek K. (1998):** Fatigue in primary biliary cirrhosis. *Gut* 43(5):705–710.
- 37.**Chapman R.W., Arborgh B.A., Rhodes J.M. et al. (1980):** Primary sclerosing cholangitis: A review of its clinical features, cholangiography, and hepatic histology. *Gut*; 21:870-7.
- 38.**Charatcharoenwitthaya P. and Lindor K.D. (2006):** Primary sclerosing cholangitis: Diagnosis and management. *Curr Gastroenterol Rep*; 8:75-82.
- 39.**Colhoun H., McKeigue P.M., Smith G.D. (2003):** Problems of reporting genetic associations with complex outcomes. *Lancet*; 361: 865-872.
- 40.**Colina F. (1992):** Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. *Gastroenterology* 102(4 Pt 1):1319–1324.
- 41.**Collins F.S., Green E.D., Guttmacher A.E. et al. (2003):** A vision of the future of genomics research. *Nature*: 422:635-847.
- 42.**Cookson S., Constantini P.K., Clare M. et al. (1999):** Frequency and nature of cytokine gene polymorphisms in type I autoimmune hepatitis. *Hepatology*. 30:851-856.




-
- 43.**Corpechot (2006):** Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. *Hepatology* 43(5): 1118–1124.
- 44.**Corpechot C., Benlian B., Barbu V. et al. (2001):** Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis. *J Hepatol.* 35;324-328.
- 45.**Cresswell P. (1994):** Assembly, function and transport of MHC class II molecules. *Annu Rev Immunol*; 12:259-293.
- 46.**Cullen S., Chapman R. (2009):** In liver immunology principles and practice, by M.Eric Gershwin, John M. Verling and Michea P. Manns.; 249-261.
47. **Cullen S.N., Ahmad T., Armuzzi A. et al. (2002):** No association between NOD2 (CARD15) polymorphisms and susceptibility to, or progression of primary sclerosing cholangitis (Abstract). *Gut*; 51(Suppl2).
- 48.**Czaja A.J. and Carpenter H.A. (2001):** Autoimmune hepatitis with incidental features of bile duct injury. *Hepatology*; 34:659–665.
- 49.**Czaja A.J. and Carpenter H.A. (2003):** Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. *Liver Int*; 23:116–123.
- 50.**Czaja A.J. and Donaldson P.T. (2000):** Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. *Immunol Rev.* 174:250-259.
- 51.**Czaja A.J., Cassani F., Cataleta M. et al. (1997):** Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. *Digest Dis Sci*; 42:1688–1696.




52. **Czaja A.J., Donaldson P.T. and Lohse A.W. (2002):** Antibodies to soluble liver antigen-liver pancreas and HLA risk factors for type 1 AIH. *Am J gastrointrol*: 97:413-419.
53. **Danielsson A., Boqvist L. and Uddenfeldt P. (1990):** Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. *Hepatology* 11(3):458–464.
54. **Djilali-Saiah I., Renous R., Caillat-Zucman S. et al. (2004):** Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients. *J Hepatol*; 40: 904-909.
55. **Doherty D.G., Donaldson P.T., Underhill J.A. et al. (1994):** Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. *Hepatology*; 19:609-615.
56. **Donaldson P., Agarwal K., Craggs A. et al. (2001):** HLA and interleukin-1 gene polymorphisms in primary biliary cirrhosis associations with disease progression and disease susceptibility. *Gut*; 48:397-402.
57. **Donaldson P.T. (2002):** Genetics in autoimmune hepatitis. *Semin Liver Dis*; 23:353-363.
58. **Donaldson P.T. (2004):** Recent advances in clinical practice: genetics of liver disease: immunogenetics and disease pathogenesis. *Gut*: 53:599-608.
59. **Donaldson P.T. and Norris S. (2001):** Immunogenetics in PSC *Ballieres Best Pract Res in Clin Gastroenterol*; 15:611-627.




60. **Donaldson P.T. and Norris S. (2002):** Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. *Autoimmunity*. 35:555-564.
61. **Donaldson P.T., Baragiotta A., Henneghan M.A. et al. (2006):** HLA class II alleles, genotypes, haplotypes and amino acids in primary biliary cirrhosis. *Hepatology*; 44:667-674.
62. **Donaldson P.T., Farrant J.M., Wilkinson M.L. et al. (1991):** Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. *Hepatology*; 13:129-133.
63. **Donaldson P.T. (2009):** In liver immunology principles and practice, by M.Eric Gershwin, John M. Verling and Michea P. Manns.; 221-233.
64. **EASL, (2009):** Clinical practice guidelines: management of cholestatic liver diseases. *J Hepatol*. doi:10.1016/j.jhep.04.009.
65. **Elferink R.P. (1998):** Class III P-glycoproteins mediate the formation of lipoprotein X in the mouse. *J Clin Invest* 102(9):1749–1757.
66. **Etzel J.P., Eng S.C., Ko C.W. et al. (2008):** Complications after ERCP in patients with primary sclerosing cholangitis. *Gastrointest Endosc*; 67:643-8.
67. **Fainboim L., Marcos Y., Pando M. et al. (1994):** Chronic active autoimmune hepatitis in children: strong association with a particular HLA-DR6 (DRB1*1301) haplotype. *Hum Immunol*. 41:146-150.




68. **Fainboim L., Velasco M.C.C., Marcos C.Y. et al. (2001):** Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB1*1301, a marker for paediatric autoimmune hepatitis. *Hepatology*;33:1512-1517.
69. **Fan L-Y., Tu X-Q., Pfeiffer T. et al. (2005):** Genetic association of cytokine polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in Chinese. *World J Gastroenterol*; 11:2768-2772.
70. **Fodil N., Pellet P., Laloux L. et al. (1999):** MICA haplotypic diversity. *Immunogenetics*; 49:557-560.
71. **Garred P., Lyon H., Christoffersen P. et al. (1993):** Deposition of C3, the terminal complement complex and vitronectin in primary biliary cirrhosis and primary sclerosing cholangitis. *Liver*; 13:305-310.
72. **Gershwin M.E. and Mackay I.R. (2008):** The causes of primary biliary cirrhosis: convenient and inconvenient truths. *Hepatology* 47 (2):737–745.
73. **Gorelik M., Debski R. and Frangoul H. (2004):** Autoimmune hemolytic anemia with giant cell hepatitis: case report and review of the literature. [Review] [22 refs]. *J Pediatr Hematol/Oncol*; 26:837–839.
74. **Gossard A.A., Angulo P., Lindor K.D. (2005):** Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. *Am J Gastroenterol*; 100:1330-1333.
75. **Goudie B.M. (1985):** Breast cancer in women with primary biliary cirrhosis. *Br Med J (Clin Res Ed)* 291(6509): 1597–1598.




76. **Graham A.M., Dollinger M.M., Howie S.E.M. et al. (2000):** Identification of novel alleles at a polymorphic microsatellite repeat region in the human NRAMPI gene promoter: analysis of allele frequencies in primary biliary cirrhosis. *J Med Genet.* 37: 150-152.
77. **Gregorio G.V., Portmann B., Karani J. et al. (2001):** Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. *Hepatology*; 33: 544–553.
78. **Groh V., Bahram S., Bauer S. et al. (1996):** Cell stress regulated human major histocompatibility complex class I gene-regulated in gastrointestinal epithelium. *Proc Natl Acad Sci USA.*; 93: 12445-12450.
79. **Haines J.L. and Pericak-Vance M.A. (1998):** Overview of mapping common and genetically complex disease genes. In: Haines JL. Pericak-Vince MA. eds. *Approaches to Gene Mapping in Complex Diseases*. New York. USA: John Wiley & Sons, 1998: 1-16.
80. **Hashimoto E., Lindor K.D., Homburger H.A. et al. (1993):** Immuno-histochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. *Mayo Clin Proc*: 68:1049-1055.
81. **Hirschhorn J.N., Lohmueller K., Bryne E. et al. (2002):** A comprehensive review of genetic association studies. *Genet Med*; 2: 45-61.




- 82.**Hodgson S.F. (1985):** Bone loss and reduced osteoblast function in primary biliary cirrhosis. *Ann Intern Med* 103(6 (Pt 1)):855–860.
- 83.**Horton R., Wilming L., Rand V. et al. (2004):** Gene map of the extended human MHC. *Nat Rev Genet*; 5:889-899.
- 84.**Huet P.M. (2000):** Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. *Am J Gastroenterol* 95 (3):760–767.
- 85.**Huet P.M. (2008):** Portal hypertension and primary biliarycirrhosis: effect of long-term ursodeoxycholic acid treatment *Gastroenterology* 135(5): 1552–1560.
- 86.**Hurlburt K.J. (2002):** Prevalence of autoimmune liver diseasein Alaska Natives. *Am J Gastroenterol* 97(9):2402–2407.
- 87.**Invernizzi P., Battezzati P.M., Crosignani A. et al. (2003):** Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. *Journal of Hepatology*. 38:401-406.
- 88.**Invernizzi P., Selmi C., Poli F. et al. (2005):** HLA DRB1 polymorphisms in 676 Italian patients with primary biliary cirrhosis and 2028 matched healthy controls. A nation-wide population based case-control study. *Hepatology*; 42-462A.
- 89.**James O.F. (1999):** Primary biliary cirrhosis once rare, nowcommon in the United Kingdom? *Hepatology* 30(2): 390–394.
- 90.**Johnson G.C.L., Esposito L., Barratt B.J. et al. (2001):** Haplotype tagging for lthe identification of common disease genes. *NaT Genet*; 29; 233 -237.




-
91. **Johnson P.J. and McFarlane I.G. (1993):** Meeting report: International Autoimmune Hepatitis Group. *Hepatology*; 18: 998–1005.
92. **Jones D.E. (2007):** Pathogenesis of primary biliary cirrhosis. *Gut* 56(11):1615–1624.
93. **Jones D.E.J. (2007):** Fatigue in cholestatic liver disease: is it all in the mind? *J Hepatol* 46:992–994.
94. **Jones D.E.J. and Donaldson P.T. (2003):** Genetic factors in the pathogenesis of primary biliary cirrhosis. *Clin Liver Dis*; 7:841-864.
95. **Jorde R., Rekvig O.P. and Bostad L. et al. (1986):** A follow-up study of 68 patients with anti-mitochondrial antibodies (AMA). *Acta Med Scand* 220(3):241–247.
96. **Kaplan G.G., Laupland K.B., Butzner D. (2007):** The burden of large and small duct primary sclerosing cholangitis in adults and children: A population-based analysis. *Am J Gastroenterol*; 102:1042-9.
97. **Kaplan M.M. (1987):** Primary biliary cirrhosis. *N Engl J Med* 316 (9):521–528.
98. **Kaplan M.M. and Gershwin M.E. (2005):** Primary biliary cirrhosis. *N Engl J Med* 353 (12): 1261-1273. doi: 10. 1056/ NEJMra 043898.
99. **Kapsenberg M.L. (2003):** Dendritic cell control of pathogen-driven T-cell polarization. *Nat Rev immunol*; 3:984-993.
100. **Karvonen M. (1993):** A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. World Health Organization Diamond Project Group. *Diabetologia* 36(10): 883–892.




101. **Kawakami T. and Galli S.J. (2002):** Regulation of mast cell and basophil function and survival by IgE. *Nat Rev Immunol*; 2:773-786.
102. **Keane-Myers A., Casolaro V., Ono S.J. (1998):** Molecular basis and role of differential cytokine production in T helper cell subsets in immuno-logic disease. *Adv Exp Med Biol*; 438:479-484.
103. **Kikuchi K. (2005):** Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. *Gastroenterology* 128(2): 304–312.
104. **Kim W.R. (2000):** Epidemiology and natural history of primary biliary cirrhosis in a US community. *Gastroenterology* 119(6):1631–1636.
105. **Kim W.R., Therneau T.M., Wiesner R.H. et al. (2000):** A revised natural history model for primary sclerosing cholangitis. *Mayo Clin Proc*; 75:688-94.
106. **Kingham J.G. and Parker D.R. (1998):** The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. *Gut* 42(1):120–122.
107. **Kingham J.G., Kochar N. and Gravenor M.B. (2004):** Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. *Gastroenterology*; 126: 1929-30.
108. **Klein R.L.M., Leuschner U., Berg P.A. (1997):** TH1 and TH2-cytokine profiles in autoimmune liver disorders. *J Hepatol*; 26:112.




-
109. **Kremer A.E. (2008):** Pathogenesis and treatment of pruritus incholestasis. *Drugs* 68(15): 2163–2182.
110. **Kristiansen O.P., Larsen Z.M. and Pocoit F. (2000):** CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity? *Genes Immun*; 1:170-184.
111. **Kuiper (2009):** Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. *Gastroenterology* 136(4):1281–1287.
112. **Lacerda M.A. (1995):** Antimitochondrial antibody-negativeprimary biliary cirrhosis. *Am J Gastroenterol* 90(2): 247–249.
113. **Laurin J.M. (1994):** The natural history of abdominal pain associated with primary biliary cirrhosis. *Am J Gastroenterol* 89(10):1840–1843.
114. **Lazaridis K.N. and Talwalkar J.A. (2007):** Clinical epidemiology ofprimary biliary cirrhosis: incidence, prevalence, and impact of therapy. *J Clin Gastroenterol* 41(5):494–500.
115. **Lee Y.M. and Kaplan M.M. (2005):** The natural history of PBC: has itchanged? *Semin Liver Dis* 25(3):321–326.
116. **Liu Y-J., Kanzler H., Soumelis V. et al.(2001):** Dendritic cell lineage, plasticity and cross regulation. *Nat Immunol*; 2: 585-589.
117. **Longhi M.S., Hussain M.J., Mitry R.R. et al. (2006):** Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. *J Immunol*; 176:4484-4491.




-
118. **Loof L. (1994):** Cancer risk in primary biliary cirrhosis: apopulation-based study from Sweden. *Hepatology* 20(1 Pt1): 101–104.
119. **Lucena J.F. (2003):** A multidrug resistance 3 gene mutationcausing cholelithiasis, cholestasis of pregnancy, and adulthoodbiliary cirrhosis. *Gastroenterology* 124(4): 1037–1042.
120. **Ludwig J., Dickson E.R.and McDonald G.S. et al (1978):** Staging of chronicnonsuppurative destructive cholangitis (syndrome of primarybiliary cirrhosis). *Virchows Arch A Pathol Anat Histol* 379 (2):103–112.
121. **MacCarty R.L., LaRusso N.Fand Wiesner R.H. (1983):** Primary sclerosing cholangitis: Findings on cholangiography and pancreatography. *Radiology*; 149:39-44.
122. **Mackay C.R. (2001):** Chemokines: immunology's high impact factors. *Nat Immunol*; 2:95-101.
123. **Mackay I.R. and Morris P.J. (1972):** Association of autoimmune active hepatitis with HL-A1. 8. *Lancet*; ii:793-795.
124. **Manns M.P., Bremm A., Schneider P.M. et al. (1991):** HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. *Gastroenterology*; 101:1367-1373.
125. **Marceau G., Lapierre P., Beland K. et al. (2005):** LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? *Hepatology*; 42: 675–682.
126. **Martins E.B.H.C., Chapman R.W., Fleming K. (1994):** Increased activation of peripheral blood and liver T-Iymphocytes in patients with primary sclerosing cholangitis and autoimmune liver diseases. *Hepatology*; 19:981.




127. **McFarlane I.G. (2002):** Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. *Clin Liver Dis*; 6:317–333.
128. **McGovern D.P.B., Hysi P., Ahmad T. et al. (2005):** Association between a complex insertion/deletion polymorphism in NODI (CARD4) and susceptibility to inflammatory bowel disease. *Hum Mol Genet*; 14:1245-1250.
129. **Mehta S.N., Reinhold C. and Barkun A.N. (1997):** Magnetic resonance cholangiopancreatography. *Gastrointest Endosc Clin N Am*; 7:247-70.
130. **Metcalf J.V.(1996):** Natural history of early primary biliarycirrhosis. *Lancet* 348(9039):1399–1402.
131. **Milkiewicz P. and Heathcote E.J. (2004):** Fatigue in chronic cholestasis. *Gut* 53(4):475–477.
132. **Mills K.H. (2004):** Regulatory T cells: friend or foe in immunity to infection? *Nat Rev Immunol*; 4:841-855.
133. **Mitchell S.A., Chapman R.W. (2000):** Primary sclerosing cholangitis. *Clin Rev Allergy Immunol*; 18:185-214.
134. **Mitchison H.C. (1986):** Positive antimitochondrial antibodybut normal alkaline phosphatase: is this primary biliary cirrhosis? *Hepatology* 6(6):1279–1284.
135. **Mukai T., Kimura A., Ishibashi H. et al. (1995):** Association of HLA-DRB1'0803 and '1602 with susceptibility to primary biliary cirrhosis. *Int Hepatol Comm*; 3:207-212.
136. **Munoz S.J. (1989):** Vitamin E deficiency in primary biliarycirrhosis: gastrointestinal malabsorption, frequency and relationship to other lipid-soluble vitamins. *Hepatology* 9(4):525–531.




-
137. **Murphy K.M. and Reiner S.L. (2002):** The lineage decisions of helper T cells. *Nat Rev Immunol*; 2:933-944.
138. **Nakano T. (2002):** Long-term prognosis of primary biliarycirrhosis (PBC) in Japan and analysis of the factors of stageprogression in asymptomatic PBC (a-PBC). *Hepatol Res* 22 (4):250–260.
139. **NCB1 Single Nucleotide Polymorphism (2007):** <http://www.ncbi.nlm.nih.gov/SNP/>. Last accessed May 21. 2007.
140. **Nepom G.T. (2000):** HLA and rheumatoid arthritis. In: Warrens A. Lechler R. eds. *HLA in Health and Disease*. London: Academic Press,181-186.
141. **Newton J.L. (2008):** A predictive model for fatigue and itsaetiologica associations in primary biliary cirrhosis. *Clin Gastroenterol Hepatol* 6:228–233.
142. **Nishio A., Keefe E.B. and Gershwin M.E. (2002):** Immunopathogenesis of primary biliary cirrhosis. *Semin Liver Dis* 22(3):291-302.
143. **Norris S., Doherty D.G., McEntee G.et al. (1999):** Natural T cells in the human liver: cytotoxic lymphocytes with dual T cell and natural killer cell phenotvpe and function are phenotypically heterogeneous and include Va24JaQ and T cell receptor bearing cells. *Hum Immunol*; 60: 20-31.
144. **Norris S., Kondeatis E., Collins R. el al. (2001):** Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. *Gasroentrology*; 120:1475-1482.




-
145. **Noun-Aria K.T., Donaldson P.T., Hegarty J.E. et al. (1985):** HLA A1-B8-DR3 and suppressor cell function in first-degree relatives of patients with autoimmune chronic active hepatitis. *J Hepatol*; 1:235-241.
146. **O'Farrelly C.G., Doherty D. (2009):** In liver immunology principles and practice, by M.Eric Gershwin, John M. Verling and Michea P. Manns.; 15-24
147. **Olsson R., Broome U., Danielsson A. et al. (1999):** Spontaneous course of symptoms in primary sclerosing cholangitis: Relationships with biochemical and histological features. *Hepatogastroenterology*; 46:136-41.
148. **Olsson R., Danielsson A., Jarnerot G. et al. (1991):** Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. *Gastroenterology*; 100:1319-23.
149. **Oplez G., Votgen A.G.M., Summerskill W.H.J. et al. (1977):** HLA determinant in chronic active liver disease: a possible relation of HLA-Dw3 to prognosis. *Tissue Antigens*; 9:36-10.
150. **Ota M., Seki T., Kiyosawa K. et al. (1992):** A possible association between basic amino acids at position 13 of DRBI chains and autoimmune hepatitis. *Immunogenetics*; 36:49-55.
151. **Padgett K.A., Selmi C., Kenny T.P. et al. (2005):** Phylogenic and immunological definition of four lipoylated proteins from *Novospingobium aromaticivorans*, implications for primary biliary cirrhosis. *J Autoimmun*; 24:209-219.




152. **Panasiuk A., Prokopowicz D., Zak J. et al. (2004):** Lymphocyte subpopulations in peripheral blood in primary sclerosing cholangitis. *Hepatogastroenterology*; 51:1289-1291.
153. **Pando M., Lariba J., Fernandez. G.C. et al. (1999):** Paediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. *Hepatology*: 30:1374-1380.
154. **Perrow K.A. (2005):** Genetic polymorphism of the immunoregulatory system with specific reference to apoptosis. Thesis submitted for the degree of Doctor of Philosophy. University of Newcastle.
155. **Pestka S., Krause C.D., Sarkar D. et al. (2004):** Interleukin-10 and related cytokines and receptors. *Annu Rev Immunol*; 22:929-979.
156. **Poupon R.E. (1993):** Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. *Hepatology* 17 (4): 577-582.
157. **Pratt D.S., Frwaz K.A., Rabson A. et al. (1997):** A novel histological lesion in glucocorticoid-responsive chronic hepatitis. *Gastroenterology*; 113:664–668.
158. **Prince M.I. (2004):** Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. *Gut* 53(6):865–870.
159. **Prince M.I., Jones D.E. (2000):** Primary biliary cirrhosis: new perspectives in diagnosis and treatment. *Postgrad Med J* 76 (894): 199–206.




-
160. **Roll J. (1983):** The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. *N Engl J Med* 308(1):1–7.
161. **Russo E. (2003):** The new approach to autoimmune disease. *Scientist*: May:30-31.
162. **Rust C. and Gores G.J. (2000):** Apoptosis and liver disease. *Am J Med*: 108:567- 574
163. **Sanchez-Urdazpal L., Czaja A.J., van Hock B. et al. (1992):** Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. *Hepatology*; 15: 215-221.
164. **Schaekal N.A., McGuinness P.H., Abbott C.A. et al.(2001):** McCaughan GW. Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. *Gut* 2001; 49:565-576.
165. **Schatz D.G. and Sanopoulou E. (2005):** Biochemistry of V(D)J recombination. *Curr Top Microbial Immunol*; 290:49-85.
166. **Scheuer P.J. (1983):** Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. *Postgrad Med J* 59(Suppl 4): 106–115.
167. **Scheuer P.J. (1998):** Ludwig Symposium on biliary disorders-part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. *Mayo Clin Proc*; 73:179-83.




-
168. **Schrumpf E. and Boberg K.M. (2001):** Epidemiology of primary sclerosing cholangitis. *Best Pract Res Clin Gastroenterol*; 15:553-62.
169. **Schwartz R.H. (2003):** T cell anergy. *Annu Rev Immunol*; 21 : 305-334.
170. **Searle S. and Black Well J.M. (1999):** Evidence for a functional repeat polymorphism in the promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious disease susceptibility *J Med Genet*; 36:295-299.
171. **Segal A.W. (2005):** How neutrophils kill microbes. *Annu Rev Immunol*; 23:197-223.
172. **Seki T., Ota M., Furuta S. et al. (1992):** HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients *Gastroenterology*.103:1041-1047.
173. **Selmi C., Balkwill D.L., Invernizzi et al. (2003):** Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolising bacterium. *Hepatology*; 38:1250-1257.
174. **Selmi C., Lio A., Invernizzi P. et al. (2009):** In liver immunology principles and practice, by M. Eric Gershwin, John M. Verling and Michea P.Manns.; 235-247.
175. **Shapiro J.M., Smith H. and Schaffner F. (1979):** Serum bilirubin: a prognostic factor in primary biliary cirrhosis. *Gut* 20(2):137– 140.
176. **Sherlock S. and Scheuer P.J. (1973):** The presentation and diagnosis of 100 patients with primary biliary cirrhosis. *N Engl J Med* 289 (13):674–678.




-
177. **Shibuya A. (2002):** Hepatocellular carcinoma and survival inpatients with primary biliary cirrhosis. *Hepatology* 35(5):1172–1178.
178. **Shimoda S. (2008):** CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis. *J Autoimmun* 31(2):110–115.
179. **Silveira and Lindor (2008):** 690 *Can J Gastroenterol* Vol 22 No 8 August.
180. **Simpson K.J., Lukaes N.W., Colletti I. et al. (1997):** Cytokines and the liver: *J Hepatol*; 27:1120- 1132.
181. **Singh R., Nair S., Farr G. et al. (2002):** Acute autoimmune hepatitis presenting with centrilobular liver disease: case report and review of the literature. *Am J Gastroenterol*; 97:2670–2673.
182. **Sorokin A., Brown J.L. and Thompson P.D. (2007):** Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. *Atherosclerosis* 194(2):293–299.
183. **Spicuglia S., Franchini D.M. and Ferrier P. (2006):** Regulation of V(D)J recombination. *Curr Opin Immunol*; 18:158-163.
184. **Spirli C., Fabris L., Duner E. et al. (2003):** Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. *Gastroenterology*; 124:737-753.
185. **Springer J.E. (2000):** Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. *Gastroenterology* 118(1):145–151.




186. **Spurkland A., Saarinen S., Boberg K.M. et al. (1999):** HLA class II haplo-types in primary sclerosing cholangitis patients from five European populations. *Tissue Antigens*; 53:459-469.
187. **Stone J., Wade J.A., Cauch-Dudek K. et al. (2002):** Human leucocyte antigen class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA negative primary biliary cirrhosis. *J Hepatol.* 36:8-13.
188. **Strettell M.D.J., Donaldson P.T., Thompson L.J. et al. (1997):** Allelic basis for HLA-encoded susceptibility to type I autoimmune hepatitis. *Gastroenterology*; 112:2028-2035.
189. **Su T.C., Hwang J.J. and Kao J.H. (2007):** Hypercholesterolemia in primary biliary cirrhosis. *N Engl J Med* 357(15): 1561–1562.
190. **Talwalkar J.A. (2003):** Natural history of pruritus in primarybiliary cirrhosis. *Clin Gastroenterol Hepatol* 1(4): 297–302.
191. **Talwalkar J.A. and Lindor K.D. (2003):** Primary biliary cirrhosis. *Lancet* 362 (9377): 53–61.
192. **Talwalkar J.A. and Lindor K.D. (2005):** Primary sclerosing cholangitis. *Inflamm Bowel Dis*; 11:62-72.
193. **Talwalkar J.A., Angulo P., Johnson C.D. et al. (2004):** Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. *Hepatology*; 40:39-45.
194. **Tapia-Conyer R., Santos J.L., Cavalcanti A.M. et al. (1999):** Hepatitis A in Latin America: a changing epidemiologic pattern. *Am J Trop Med Hyg*; 61:825-829.



-
195. **Terjung B., Spengler U., Sauerbruch T. et al. (2005):** "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. *Gastroenterology*; 119:310-322.
196. **The Anthony Nolan Trust. (2007):** www.anthonynolan.com/HHH/nomenclature. Last accessed May 21.
197. **Toda G., Zeniya M., Watanabe F. et al. (1997):** Present status of autoimmune hepatitis in Japan—correlating the characteristics with international criteria in an area with a high rate of HCV infection. *J Hepatol*; 26:1207– 1212.
198. **Trombetta E.S. and Mellman I. (2005):** Cell biology of antigen processing invitro and invivo. *Annu Rev Immunol* 2005; 23: 975-1028.
199. **Ueda H., Howson J.M.M., Esposito L. et al. (2003):** Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. *Nature*. 423:506-511.
200. **Vazquez-Garcia M.N., Alaez C., Olivo A. et al. (1998):** MHC class sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. *J Hepatol*: 28:985-990.
201. **Vento S., Hegarty J.E., Bottazzo G. et al. (1984):** Antigen specific suppressor cell function in autoimmune chronic active hepatitis. *Lancet*; 1:1200-1204.
202. **Vergani D. and Mieli-Vergani G. (2009):** In liver immunology principles and practice, by M.Eric Gershwin, John M. Verling and Michea P. Manns.; 263-275.



203. **Vergani D., Choudhuri K., Bogdanos D.P. et al. (2002):** Pathogenesis of autoimmune hepatitis. *Clin Liver Dis*; 6: 727-737.
204. **Verma S., Guuwan B., Mendler M. et al. (2004):** Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. *Am J Gastroenterol*; 99:1510–1516.
205. **Vermeire S., Rutgeerts P. (2005):** Current status of genetics research in inflammatory bowel disease. *Genes Immun*; 6:637-645.
206. **Vogel A., Strasbug C.P. and Manns M.P. (2002):** Genetic association of vitamin D receptor polymorphism with primary biliary cirrhosis and autoimmune hepatitis. *Hepatology*; 35:126-131.
207. **Wassmuth R., Depner F., Danielsson A. et al. (2002):** HLA class II markers and clinical heterogeneity in Swedish patients with primary biliary cirrhosis. *Tissue Antigens*; 59:381-387.
208. **Watson R.G. (1995):** Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group. *Gut* 36(6):927–930. doi:10.1136/gut.36.6.927.
209. **Wen L., Ma Y., Bogdanos D.P. et al. (2001):** Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. *Curr Mol Med*; 1:379-389.
210. **Wiencke K., Boberg K.M., Donaldson P. et al. (2006):** No major effect of the CD28/CTLA4/ICOS gene region on susceptibility to primary sclerosing cholangitis *Scand J Gastroenterol*; 41:586 591.



211. **Wiencke K., Louka A.S., Spurkland A.et al. (2004):** Association of matrix metalloproteinase-1 and -3 promoter polymorphisms with clinical subsets of Norwegian primary sclerosing cholangitis patients. *J Hepatol*; 41:209-214.
212. **Wiesner R.H. (1994):** Current concepts in primary sclerosing cholangitis. *Mayo Clin Proc*; 69:969-82.
213. **Witt-Sullivan H.(1990):** The demography of primary biliarycirrhosis in Ontario, Canada. *Hepatology* 12(1):98–105.
214. **Wong B. and Pamer E.G. (2005):** CD8 T cell responses to infectious pathogens. *Annu Rev Immunol* 2003; 21:29-70.
10. Yewdell JW, Haeryfar SM. Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. *Annu Rev Immunol* 2005; 23:651-682.
215. **Xang X., Cullen S.N., Li J.H.et al. (2004):** Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of the intercellular adhesion molecule-1. *J Hepatol*; 40: 375-379.
216. **Yeaman S.J., Kirby J.A. and Jones D.E. (2000):** Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis. *Immunol Rev* 174: 238–249.
217. **Zauli D. (1987):** An autoantibody profile in primary sclerosing cholangitis. *J Hepatol* 5(1):14–18. doi:10.1016/ S0168-8278 (87)80055-7.
218. **Zen Y., Harada K., Sasaki M. et al. (2005):** Are bile duct lesions of primary biliary cirrhosis distinguishable from those of autoimmune hepatitis? Interobserver histological agreement on trimmed bile ducts. *J Gastroenterol*; 40: 164–170.